122 related articles for article (PubMed ID: 38325551)
1. Computational Pathology for Prediction of Isocitrate Dehydrogenase Gene Mutation from Whole Slide Images in Adult Patients with Diffuse Glioma.
Zhao Y; Wang W; Ji Y; Guo Y; Duan J; Liu X; Yan D; Liang D; Li W; Zhang Z; Li ZC
Am J Pathol; 2024 May; 194(5):747-758. PubMed ID: 38325551
[TBL] [Abstract][Full Text] [Related]
2. Natural language processing to predict isocitrate dehydrogenase genotype in diffuse glioma using MR radiology reports.
Kim M; Ong KT; Choi S; Yeo J; Kim S; Han K; Park JE; Kim HS; Choi YS; Ahn SS; Kim J; Lee SK; Sohn B
Eur Radiol; 2023 Nov; 33(11):8017-8025. PubMed ID: 37566271
[TBL] [Abstract][Full Text] [Related]
3. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
4. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
[TBL] [Abstract][Full Text] [Related]
5. Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics.
Choi YS; Bae S; Chang JH; Kang SG; Kim SH; Kim J; Rim TH; Choi SH; Jain R; Lee SK
Neuro Oncol; 2021 Feb; 23(2):304-313. PubMed ID: 32706862
[TBL] [Abstract][Full Text] [Related]
6. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
8. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
Choi KS; Choi SH; Jeong B
Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834
[TBL] [Abstract][Full Text] [Related]
9. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
[TBL] [Abstract][Full Text] [Related]
11. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
12. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
14. An Intra- and Inter-Modality Fusion Model Using MR Images for Prediction of Glioma Isocitrate Dehydrogenase (IDH) Mutation.
Shi X; Zhang X; Iwamoto Y; Cheng J; Bai J; Zhao G; Chen YW
Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():198-202. PubMed ID: 36086447
[TBL] [Abstract][Full Text] [Related]
15. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
16. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
17. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
18. Residual Convolutional Neural Network for the Determination of
Chang K; Bai HX; Zhou H; Su C; Bi WL; Agbodza E; Kavouridis VK; Senders JT; Boaro A; Beers A; Zhang B; Capellini A; Liao W; Shen Q; Li X; Xiao B; Cryan J; Ramkissoon S; Ramkissoon L; Ligon K; Wen PY; Bindra RS; Woo J; Arnaout O; Gerstner ER; Zhang PJ; Rosen BR; Yang L; Huang RY; Kalpathy-Cramer J
Clin Cancer Res; 2018 Mar; 24(5):1073-1081. PubMed ID: 29167275
[No Abstract] [Full Text] [Related]
19. A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
Bangalore Yogananda CG; Shah BR; Vejdani-Jahromi M; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
Neuro Oncol; 2020 Mar; 22(3):402-411. PubMed ID: 31637430
[TBL] [Abstract][Full Text] [Related]
20. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
